{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:50:44Z","timestamp":1788828644122,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Salvia-Nelumbinis naturalis (SNN), the extract of Chinese herbal medicine, has shown effects on NAFLD. This study aims to explore the underlying mechanism of SNN for regulating the lipid metabolism disorder in NAFLD based on the SIRT1\/AMPK signaling pathway.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Male C57BL\/6J mice fed with a high-fat diet (HFD) were used to establish the NAFLD model. Dynamic changes of mice including body weight, liver weight, serological biochemical indexes, liver histopathological changes, and protein level of AMPK and SIRT1 were monitored. After18 weeks, SNN treatment was administrated to the NAFLD mice for another 4 weeks. Besides the aforementioned indices, TC and TG of liver tissues were also measured. Western blot and quantitative RT-PCR were used to detect the expression and\/or activation of SIRT1 and AMPK, as well as the molecules associated with lipid synthesis and \u03b2-oxidation. Furthermore, AML12 cells with lipid accumulation induced by fatty acids were treated with LZG and EX527 (SIRT1 inhibitor) or Compound C (AMPK inhibitor ) to confirm the potential pharmacological mechanism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Dynamic observation found the mice induced by HFD with gradually increased body and liver weight, elevated serum cholesterol, hepatic lipid accumulation, and liver injury. After 16 weeks, these indicators have shown obvious changes. Additionally, the hepatic level of SIRT1 and AMPK activation was identified gradually decreased with NAFLD progress. The mice with SNN administration had lower body weight, liver weight, and serum level of LDL-c and ALT than those of the NAFLD model. Hepatosteatosis and hepatic TG content in the liver tissues of the SNN group were significantly reduced. When compared with control mice, the NAFLD mice had significantly decreased hepatic expression of SIRT1, p-AMPK, p-ACC, ACOX1, and increased total Acetylated-lysine, SUV39H2, and SREBP-1c. The administration of SNN reversed the expression of these molecules.<jats:italic>In vitro<\/jats:italic>experiments showed the effect of SNN in ameliorating hepatosteatosis and regulating the expression of lipid metabolism-related genes in AML12 cells, which were diminished by EX527 or Compound C co-incubation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Taken together, the SIRT1\/AMPK signaling pathway, involved in hepatic lipid synthesis and degradation, plays a pivotal role in the pathogenesis of NAFLD development. The regulation of SIRT1\/AMPK signaling greatly contributes to the underlying therapeutic mechanism of SNN for NAFLD.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12906-022-03697-9","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T11:03:34Z","timestamp":1660043014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Salvia-Nelumbinis naturalis improves lipid metabolism of NAFLD by regulating the SIRT1\/AMPK signaling pathway"],"prefix":"10.1186","volume":"22","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"3697_CR1","doi-asserted-by":"crossref","unstructured":"Hassan K, Bhalla V, El Regal ME, A-Kader HH: Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol 2014, 20(34):12082-12101.","DOI":"10.3748\/wjg.v20.i34.12082"},{"issue":"3","key":"3697_CR2","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1053\/j.gastro.2021.04.074","volume":"161","author":"F Kanwal","year":"2021","unstructured":"Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, et al. Preparing for the NASH Epidemic: A Call to Action. Gastroenterology. 2021;161(3):1030\u20131042 e1038.","journal-title":"Gastroenterology"},{"issue":"7","key":"3697_CR3","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1053\/j.gastro.2020.01.051","volume":"158","author":"BA Neuschwander-Tetri","year":"2020","unstructured":"Neuschwander-Tetri BA. Therapeutic Landscape for NAFLD in 2020. Gastroenterology. 2020;158(7):1984\u20131998 e1983.","journal-title":"Gastroenterology"},{"issue":"2","key":"3697_CR4","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/hep.31518","volume":"73","author":"H Tilg","year":"2021","unstructured":"Tilg H, Adolph TE, Moschen AR. Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. Hepatology. 2021;73(2):833\u201342.","journal-title":"Hepatology"},{"key":"3697_CR5","doi-asserted-by":"crossref","unstructured":"Guo WW, Wang X, Chen XQ, Ba YY, Zhang N, Xu RR, et al. Flavonones from Penthorum chinense Ameliorate Hepatic Steatosis by Activating the SIRT1\/AMPK Pathway in HepG2 Cells. Int J Mol Sci. 2018;19(9).","DOI":"10.3390\/ijms19092555"},{"issue":"4","key":"3697_CR6","first-page":"3121","volume":"16","author":"T Shen","year":"2018","unstructured":"Shen T, Xu B, Lei T, Chen L, Zhang C, Ni Z. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1\/AMPKalpha pathway. Exp Ther Med. 2018;16(4):3121\u20138.","journal-title":"Exp Ther Med"},{"issue":"10","key":"3697_CR7","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/nrm2249","volume":"8","author":"DG Hardie","year":"2007","unstructured":"Hardie DG. AMP-activated\/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007;8(10):774\u201385.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"3697_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.tem.2013.12.001","volume":"25","author":"HC Chang","year":"2014","unstructured":"Chang HC, Guarente L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab. 2014;25(3):138\u201345.","journal-title":"Trends Endocrinol Metab"},{"issue":"5","key":"3697_CR9","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1159\/000493650","volume":"49","author":"CJ Liou","year":"2018","unstructured":"Liou CJ, Wei CH, Chen YL, Cheng CY, Wang CL, Huang WC. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1\/AMPK and Fatty Acid \u03b2-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice. Cell Physiol Biochem. 2018;49(5):1870\u201384.","journal-title":"Cell Physiol Biochem"},{"key":"3697_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.nano.2019.01.013","volume":"17","author":"S Dogra","year":"2019","unstructured":"Dogra S, Kar AK, Girdhar K, Daniel PV, Chatterjee S, Choubey A, et al. Zinc oxide nanoparticles attenuate hepatic steatosis development in high-fat-diet fed mice through activated AMPK signaling axis. Nanomedicine. 2019;17:210\u201322.","journal-title":"Nanomedicine"},{"issue":"10","key":"3697_CR11","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1021\/acs.jmedchem.9b01701","volume":"63","author":"FA Romero","year":"2020","unstructured":"Romero FA, Jones CT, Xu Y, Fenaux M, Halcomb RL. The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. J Med Chem. 2020;63(10):5031\u201373.","journal-title":"J Med Chem"},{"key":"3697_CR12","volume":"2013","author":"J Pan","year":"2013","unstructured":"Pan J, Wang M, Song H, Wang L, Ji G. The efficacy and safety of traditional chinese medicine (jiang zhi granule) for nonalcoholic Fatty liver: a multicenter, randomized, placebo-controlled study. Evid Based Complement Alternat Med. 2013;2013:965723.","journal-title":"Evid Based Complement Alternat Med"},{"key":"3697_CR13","volume":"2013","author":"M Wang","year":"2013","unstructured":"Wang M, Sun S, Wu T, Zhang L, Song H, Hao W, et al. Inhibition of LXRalpha\/SREBP-1c-Mediated Hepatic Steatosis by Jiang-Zhi Granule. Evid Based Complement Alternat Med. 2013;2013:584634.","journal-title":"Evid Based Complement Alternat Med"},{"key":"3697_CR14","doi-asserted-by":"crossref","first-page":"9208314","DOI":"10.1155\/2017\/9208314","volume":"2017","author":"X Shu","year":"2017","unstructured":"Shu X, Wang M, Xu H, Liu Y, Huang J, Yao Z, et al. Extracts of Salvia-Nelumbinis Naturalis Ameliorate Nonalcoholic Steatohepatitis via Inhibiting Gut-Derived Endotoxin Mediated TLR4\/NF-kappaB Activation. Evid Based Complement Alternat Med. 2017;2017:9208314.","journal-title":"Evid Based Complement Alternat Med"},{"key":"3697_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s12967-014-0315-x","volume":"12","author":"Y Liu","year":"2014","unstructured":"Liu Y, Song H, Wang L, Xu H, Shu X, Zhang L, et al. Hepatoprotective and antioxidant activities of extracts from Salvia-Nelumbinis naturalis against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet in mice. J Transl Med. 2014;12:315.","journal-title":"J Transl Med"},{"key":"3697_CR16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12967-014-0236-8","volume":"12","author":"L Zhang","year":"2014","unstructured":"Zhang L, Xu J, Song H, Yao Z, Ji G. Extracts from Salvia-Nelumbinis naturalis alleviate hepatosteatosis via improving hepatic insulin sensitivity. J Transl Med. 2014;12:236.","journal-title":"J Transl Med"},{"issue":"9","key":"3697_CR17","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3748\/wjg.v24.i9.992","volume":"24","author":"YY Zheng","year":"2018","unstructured":"Zheng YY, Wang M, Shu XB, Zheng PY, Ji G. Autophagy activation by Jiang Zhi Granule protects against metabolic stress-induced hepatocyte injury. World J Gastroenterol. 2018;24(9):992\u20131003.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3697_CR18","doi-asserted-by":"publisher","first-page":"13681","DOI":"10.1038\/s41598-018-31708-8","volume":"8","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Wang M, Zheng P, Tang X, Ji G. Systems pharmacology-based exploration reveals mechanisms of anti-steatotic effects of Jiang Zhi Granule on non-alcoholic fatty liver disease. Sci Rep. 2018;8(1):13681.","journal-title":"Sci Rep"},{"issue":"10","key":"3697_CR19","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537\u201364.","journal-title":"Cell"},{"key":"3697_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112181","volume":"143","author":"W Zhou","year":"2021","unstructured":"Zhou W, Zhu Z, Xiao X, Li C, Zhang L, Dang Y, et al. Jiangzhi Granule attenuates non-alcoholic steatohepatitis by suppressing TNF\/NFkappaB signaling pathway-a study based on network pharmacology. Biomed Pharmacother. 2021;143:112181.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"3697_CR21","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/hep.24127","volume":"53","author":"EM Brunt","year":"2011","unstructured":"Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, Network NCR. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53(3):810\u201320.","journal-title":"Hepatology"},{"issue":"3","key":"3697_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274\u201385.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"3697_CR23","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1002\/ptr.6743","volume":"34","author":"M Gu","year":"2020","unstructured":"Gu M, Song H, Li Y, Jiang Y, Zhang Y, Tang Z, et al. Extract of Schisandra chinensis fruit protects against metabolic dysfunction in high-fat diet induced obese mice via FXR activation. Phytother Res. 2020;34(11):3063\u201377.","journal-title":"Phytother Res"},{"key":"3697_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.863756","volume":"13","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Xu J, Huang P, Yang L, Liu Y, Li Y, et al. Scoparone Improves Nonalcoholic Steatohepatitis Through Alleviating JNK\/Sab Signaling Pathway-Mediated Mitochondrial Dysfunction. Front Pharmacol. 2022;13:863756.","journal-title":"Front Pharmacol"},{"issue":"5","key":"3697_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155163","volume":"11","author":"VH Fengler","year":"2016","unstructured":"Fengler VH, Macheiner T, Kessler SM, Czepukojc B, Gemperlein K, Muller R, et al. Susceptibility of Different Mouse Wild Type Strains to Develop Diet-Induced NAFLD\/AFLD-Associated Liver Disease. PLoS One. 2016;11(5):e0155163.","journal-title":"PLoS One"},{"issue":"1","key":"3697_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1055\/s-2001-12932","volume":"21","author":"A Koteish","year":"2001","unstructured":"Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis. 2001;21(1):89\u2013104.","journal-title":"Semin Liver Dis"},{"issue":"3","key":"3697_CR27","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/ajcn\/79.3.502","volume":"79","author":"CS Lieber","year":"2004","unstructured":"Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, et al. Model of nonalcoholic steatohepatitis. Am J Clin Nutr. 2004;79(3):502\u20139.","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"3697_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1053\/j.gastro.2013.10.059","volume":"146","author":"Y Li","year":"2014","unstructured":"Li Y, Wong K, Giles A, Jiang J, Lee JW, Adams AC, et al. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology. 2014;146(2):539\u2013549 e537.","journal-title":"Gastroenterology"},{"issue":"4","key":"3697_CR29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.cmet.2009.02.006","volume":"9","author":"A Purushotham","year":"2009","unstructured":"Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009;9(4):327\u201338.","journal-title":"Cell Metab"},{"issue":"44","key":"3697_CR30","doi-asserted-by":"publisher","first-page":"33959","DOI":"10.1074\/jbc.M110.122978","volume":"285","author":"B Ponugoti","year":"2010","unstructured":"Ponugoti B, Kim DH, Xiao Z, Smith Z, Miao J, Zang M, et al. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J Biol Chem. 2010;285(44):33959\u201370.","journal-title":"J Biol Chem"},{"issue":"29","key":"3697_CR31","doi-asserted-by":"publisher","first-page":"20015","DOI":"10.1074\/jbc.M802187200","volume":"283","author":"X Hou","year":"2008","unstructured":"Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem. 2008;283(29):20015\u201326.","journal-title":"J Biol Chem"},{"issue":"2","key":"3697_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031394","volume":"7","author":"J Lee","year":"2012","unstructured":"Lee J, Hong SW, Chae SW, Kim DH, Choi JH, Bae JC, et al. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL\/6J mice. PLoS One. 2012;7(2):e31394.","journal-title":"PLoS One"},{"issue":"11","key":"3697_CR33","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.2337\/db14-0263","volume":"63","author":"F Xu","year":"2014","unstructured":"Xu F, Li Z, Zheng X, Liu H, Liang H, Xu H, et al. SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. Diabetes. 2014;63(11):3637\u201346.","journal-title":"Diabetes"},{"key":"3697_CR34","doi-asserted-by":"crossref","unstructured":"Park J, Jeon YD, Kim HL, Kim DS, Han YH, Jung Y, et al. Veratri Nigri Rhizoma et Radix (Veratrum nigrum L.) and Its Constituent Jervine Prevent Adipogenesis via Activation of the LKB1-AMPK\u03b1-ACC Axis In Vivo and In Vitro. Evid Based Complement Alternat Med. 2016;2016(8674397).","DOI":"10.1155\/2016\/8674397"},{"issue":"3","key":"3697_CR35","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s12020-014-0465-x","volume":"49","author":"S Mariani","year":"2015","unstructured":"Mariani S, Fiore D, Basciani S, Persichetti A, Contini S, Lubrano C, et al. Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients. Endocrine. 2015;49(3):711\u20136.","journal-title":"Endocrine"},{"issue":"1","key":"3697_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10020-019-0085-2","volume":"25","author":"JK Long","year":"2019","unstructured":"Long JK, Dai W, Zheng YW, Zhao SP. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1\/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Mol Med. 2019;25(1):26.","journal-title":"Mol Med"},{"issue":"6","key":"3697_CR37","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/hep.29127","volume":"65","author":"Z Fan","year":"2017","unstructured":"Fan Z, Li L, Li M, Zhang X, Hao C, Yu L, et al. The histone methyltransferase Suv39h2 contributes to nonalcoholic steatohepatitis in mice. Hepatology. 2017;65(6):1904\u201319.","journal-title":"Hepatology"},{"issue":"4","key":"3697_CR38","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41419-021-03608-9","volume":"12","author":"PY Liu","year":"2021","unstructured":"Liu PY, Chen CC, Chin CY, Liu TJ, Tsai WC, Chou JL, et al. E3 ubiquitin ligase Grail promotes hepatic steatosis through Sirt1 inhibition. Cell Death Dis. 2021;12(4):323.","journal-title":"Cell Death Dis"},{"issue":"18","key":"3697_CR39","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1101\/gad.17420111","volume":"25","author":"DG Hardie","year":"2011","unstructured":"Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011;25(18):1895\u2013908.","journal-title":"Genes Dev"},{"issue":"12","key":"3697_CR40","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/bies.10009","volume":"23","author":"DG Hardie","year":"2001","unstructured":"Hardie DG, Hawley SA. AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays. 2001;23(12):1112\u20139.","journal-title":"Bioessays"},{"issue":"6","key":"3697_CR41","first-page":"E1107","volume":"273","author":"GF Merrill","year":"1997","unstructured":"Merrill GF, Kurth EJ, Hardie DG, Winder WW. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol. 1997;273(6):E1107\u201312.","journal-title":"Am J Physiol"},{"issue":"8","key":"3697_CR42","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI13505","volume":"108","author":"G Zhou","year":"2001","unstructured":"Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167\u201374.","journal-title":"J Clin Invest"},{"issue":"5","key":"3697_CR43","doi-asserted-by":"publisher","first-page":"G852","DOI":"10.1152\/ajpgi.00521.2005","volume":"290","author":"JK Reddy","year":"2006","unstructured":"Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol. 2006;290(5):G852\u20138.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"3697_CR44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1748-1716.2009.01970.x","volume":"196","author":"B Viollet","year":"2009","unstructured":"Viollet B, Guigas B, Leclerc J, Hebrard S, Lantier L, Mounier R, et al. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf). 2009;196(1):81\u201398.","journal-title":"Acta Physiol (Oxf)"},{"key":"3697_CR45","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ejphar.2016.06.040","volume":"788","author":"EJ Park","year":"2016","unstructured":"Park EJ, Kim YM, Kim HJ, Jang SY, Oh MH, Lee DH, et al. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation. Eur J Pharmacol. 2016;788:200\u20139.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"3697_CR46","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s00125-012-2747-2","volume":"56","author":"MY Kim","year":"2013","unstructured":"Kim MY, Lim JH, Youn HH, Hong YA, Yang KS, Park HS, et al. Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1alpha axis in db\/db mice. Diabetologia. 2013;56(1):204\u201317.","journal-title":"Diabetologia"},{"issue":"41","key":"3697_CR47","doi-asserted-by":"publisher","first-page":"27628","DOI":"10.1074\/jbc.M805711200","volume":"283","author":"F Lan","year":"2008","unstructured":"Lan F, Cacicedo JM, Ruderman N, Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem. 2008;283(41):27628\u201335.","journal-title":"J Biol Chem"},{"issue":"6","key":"3697_CR48","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1007\/s00125-012-2530-4","volume":"55","author":"WL Chen","year":"2012","unstructured":"Chen WL, Kang CH, Wang SG, Lee HM. alpha-Lipoic acid regulates lipid metabolism through induction of sirtuin 1 (SIRT1) and activation of AMP-activated protein kinase. Diabetologia. 2012;55(6):1824\u201335.","journal-title":"Diabetologia"},{"issue":"6","key":"3697_CR49","first-page":"1109","volume":"42","author":"YT Pan","year":"2017","unstructured":"Pan YT, Xu FY, Yu XZ, Shang WB. Research progress on therapeutic targets of active components in Chinese herbs for treatment of nonalcoholic fatty liver disease. Zhongguo Zhong Yao Za Zhi. 2017;42(6):1109\u201312.","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"3697_CR50","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.nut.2016.09.001","volume":"34","author":"T Charytoniuk","year":"2017","unstructured":"Charytoniuk T, Drygalski K, Konstantynowicz-Nowicka K, Berk K, Chabowski A. Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials. Nutrition. 2017;34:108\u201317.","journal-title":"Nutrition"},{"key":"3697_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154161","volume":"102","author":"J Luo","year":"2022","unstructured":"Luo J, Chen S, Wang L, Zhao X, Piao C. Pharmacological effects of polydatin in the treatment of metabolic diseases: A review. Phytomedicine. 2022;102:154161.","journal-title":"Phytomedicine"},{"issue":"7","key":"3697_CR52","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/hepr.12788","volume":"47","author":"S Wang","year":"2017","unstructured":"Wang S, Li X, Guo H, Yuan Z, Wang T, Zhang L, et al. Emodin alleviates hepatic steatosis by inhibiting sterol regulatory element binding protein 1 activity by way of the calcium\/calmodulin-dependent kinase kinase-AMP-activated protein kinase-mechanistic target of rapamycin-p70 ribosomal S6 kinase signaling pathway. Hepatol Res. 2017;47(7):683\u2013701.","journal-title":"Hepatol Res"},{"key":"3697_CR53","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.2147\/DDDT.S243893","volume":"14","author":"L Yu","year":"2020","unstructured":"Yu L, Gong L, Wang C, Hu N, Tang Y, Zheng L, et al. Radix Polygoni Multiflori and Its Main Component Emodin Attenuate Non-Alcoholic Fatty Liver Disease in Zebrafish by Regulation of AMPK Signaling Pathway. Drug Des Devel Ther. 2020;14:1493\u2013506.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"3697_CR54","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3390\/ijms23031044","volume":"23","author":"A Gnoni","year":"2022","unstructured":"Gnoni A, Di Chiara SB, Giannotti L, Gnoni GV, Siculella L, Damiano F. Quercetin Reduces Lipid Accumulation in a Cell Model of NAFLD by Inhibiting De Novo Fatty Acid Synthesis through the Acetyl-CoA Carboxylase 1\/AMPK\/PP2A Axis. Int J Mol Sci. 2022;23(3):1044.","journal-title":"Int J Mol Sci"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-022-03697-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-022-03697-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-022-03697-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T01:20:07Z","timestamp":1727745607000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-022-03697-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3697"],"URL":"https:\/\/doi.org\/10.1186\/s12906-022-03697-9","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"assertion":[{"value":"26 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experimental protocols were approved by and all experiments were performed according to the guideline of the Institutional Animal Care and Use Committee of Shanghai University of Traditional Chinese Medicine (LHERAW-2019001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}